{"id":394174,"date":"2020-12-07T08:03:17","date_gmt":"2020-12-07T13:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394174"},"modified":"2020-12-07T08:03:17","modified_gmt":"2020-12-07T13:03:17","slug":"biosight-presents-updated-new-clinical-data-from-ongoing-phase-2b-study-of-aspacytarabine-bst-236-at-the-2020-ash-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biosight-presents-updated-new-clinical-data-from-ongoing-phase-2b-study-of-aspacytarabine-bst-236-at-the-2020-ash-annual-meeting\/","title":{"rendered":"Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting"},"content":{"rendered":"
\n

\n Expanded data set <\/em>
\n supports <\/em>
\n efficacy across key measures including complete remission<\/em>
\n and <\/em>
\n MRD<\/em>
\n (-) rates<\/em>
\n , duration of response and overall survival<\/em>
\n \n <\/p>\n

\n Durable responses <\/em>
\n achieved as <\/em>
\n monotherapy<\/em>
\n with limited<\/em>
\n -duration<\/em>
\n treatment <\/em>
\n of up to 4 <\/em>
\n courses <\/em>\n <\/p>\n

\n Efficacy and <\/em>
\n favorable safety profile observed<\/em>
\n in most challenging patient population<\/em>
\n ,<\/em>
\n including elderly, secondary and adverse cytogenetics AML patients, <\/em>
\n unfit for <\/em>
\n intensive <\/em>
\n chemotherapy<\/em>\n <\/p>\n

AIRPORT CITY,\u00a0Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) — Biosight Ltd.<\/a>, a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the presentation of updated clinical data from the Company\u2019s ongoing Phase 2b trial evaluating aspacytarabine (BST-236) as a single-agent first-line acute myeloid leukemia (AML) therapy for patients unfit for standard chemotherapy at the 62nd\u00a0<\/sup>American Society of Hematology (ASH) Annual Meeting and Exposition.<\/p>\n

\u201cThese exciting data provide additional evidence that aspacytarabine has the potential to transform standard of care for AML patients,\u201d said Jessica K. Altman M.D., Professor, Medicine, Feinberg School of Medicine of Northwestern University and Lead Study Investigator. \u201cThis larger data set supports our previous encouraging outcomes which are of particular interest given the challenging nature of the patient population treated. The 32% complete remission rate achieved in this population, comprised of mainly secondary AML patients including patients with prior hypomethylating agent therapy, is notable. Importantly, all responders achieved a complete hematological recovery and the MRD(-) rate by flow was 57%. And while still early, these results are important as in responders we are seeing a median duration of response not reached at 12 months, and median overall survival not reached at 24 months. These efficacy results are especially exciting to me as they are achieved in a monotherapy regimen with a limited duration of treatment of up to four courses, and a manageable safety profile.\u201d\u00a0<\/p>\n

Key presentation highlights:<\/p>\n

Poster presentation titled, \u201cDurable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation<\/em>\u201d <\/em>presented by Dr. Altman<\/p>\n